Immunologically "cold" tumors remain one of the greatest challenges in oncology, limiting the effectiveness of checkpoint inhibitors in cancers such as pla...
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Sanofi announced that the Europ...
Nurix Therapeutics, Inc. announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating b...
Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagemen...
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
Targeted genetic medicines are reshaping the future of cancer treatment by improving the precision of therapeutic delivery while addressing the challenges ...
Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) dr...
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
-Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasir...
Sanofi announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis ...
The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its own co...
Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating B...
A consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage bio...
© 2026 Biopharma Boardroom. All Rights Reserved.
